S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)

Arcellx (ACLX) Stock Forecast, Price & News

$34.66
-1.22 (-3.40%)
(As of 05:19 PM ET)
Compare
Today's Range
$34.36
$36.00
50-Day Range
$33.06
$37.40
52-Week Range
$16.97
$48.92
Volume
404,535 shs
Average Volume
497,069 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.42

Arcellx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.8% Upside
$53.42 Price Target
Short Interest
Bearish
17.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Arcellx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$201,390 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.19) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

669th out of 969 stocks

Biological Products, Except Diagnostic Industry

104th out of 161 stocks


ACLX stock logo

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

ACLX Price History

ACLX Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Should You be Bullish on Arcellx (ACLX)?
Analyst Ratings for Arcellx
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings
8/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
98
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.42
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+50.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-188,680,000.00
Pretax Margin
-568.13%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.68 per share

Miscellaneous

Free Float
45,525,000
Market Cap
$1.72 billion
Optionable
Not Optionable
Beta
-0.60
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Rami Elghandour (Age 44)
    Chairman, CEO & Pres
    Comp: $1.02M
  • Ms. Michelle Lim Gilson (Age 30)
    Chief Financial Officer
    Comp: $832.8k
  • Dr. Christopher R. Heery M.D. (Age 43)
    Chief Medical Officer
    Comp: $688.55k
  • Mr. Michael Dombeck M.B.A.
    Chief Operating Officer
  • Mr. Narinderjeet Singh M.S. (Age 51)
    Chief Technical Officer
  • Mr. David Tice Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Myesha Lacy
    VP of Investor Relations
  • Ms. Maryam Abdul-Kareem J.D.
    M.S., Gen. Counsel
  • Ms. Kate Aiken
    Chief People Officer
  • Mr. Neeraj P. Teotia (Age 48)
    Chief Commercial Officer













ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price forecast for 2023?

10 brokers have issued twelve-month price objectives for Arcellx's stock. Their ACLX share price forecasts range from $39.00 to $104.00. On average, they anticipate the company's share price to reach $53.42 in the next twelve months. This suggests a possible upside of 50.6% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2023?

Arcellx's stock was trading at $30.98 at the beginning of 2023. Since then, ACLX shares have increased by 14.5% and is now trading at $35.48.
View the best growth stocks for 2023 here
.

Are investors shorting Arcellx?

Arcellx saw a decline in short interest in September. As of September 15th, there was short interest totaling 6,200,000 shares, a decline of 6.1% from the August 31st total of 6,600,000 shares. Based on an average daily trading volume, of 440,500 shares, the days-to-cover ratio is presently 14.1 days. Currently, 17.7% of the shares of the stock are short sold.
View Arcellx's Short Interest
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.18. The business had revenue of $14.30 million for the quarter, compared to the consensus estimate of $82.38 million.

What ETFs hold Arcellx's stock?

ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED).

When did Arcellx IPO?

(ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

What is Arcellx's stock symbol?

Arcellx trades on the NASDAQ under the ticker symbol "ACLX."

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcellx's stock price today?

One share of ACLX stock can currently be purchased for approximately $35.48.

How much money does Arcellx make?

Arcellx (NASDAQ:ACLX) has a market capitalization of $1.72 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How can I contact Arcellx?

The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -